Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.33 |
| ▸ | RORC | P51449 | 2/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PREP | P48147 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1924787 | 1.00 | CHRM2 (0.41) | CHRM2CHRM1CHRM3NR1H2EPHX2 | |
| SCHEMBL5153017 | 1.00 | CHRM2 (0.41) | CHRM2CHRM1CHRM3NR1H2EPHX2 | |
| SCHEMBL376697 | 1.00 | CHRM2 (0.41) | CHRM2CHRM1CHRM3NR1H2EPHX2 | |
| SCHEMBL5203966 | 1.00 | CHRM2 (0.41) | CHRM2CHRM1CHRM3NR1H2EPHX2 | |
| SCHEMBL77478 | 1.00 | CHRM2 (0.41) | CHRM2CHRM1CHRM3NR1H2EPHX2 | |
| SCHEMBL6491588 | 1.00 | CHRM2 (0.41) | CHRM2CHRM1CHRM3NR1H2EPHX2 | |
| SCHEMBL3949211 | 1.00 | CHRM2 (0.41) | CHRM2CHRM1CHRM3NR1H2EPHX2 | |
| SCHEMBL3679572 | 0.88 | CHRM2 (0.41) | CHRM2CHRM1CHRM3NR1H2EPHX2 | |
| SCHEMBL4769152 | 0.88 | CHRM2 (0.41) | CHRM2CHRM1CHRM3NR1H2EPHX2 | |
| SCHEMBL15913256 | 0.88 | CHRM2 (0.41) | CHRM2CHRM1CHRM3NR1H2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113072542-B | ROR gamma t inhibitor and preparation method and application thereof | 广东东阳光药业股份有限公司 | 2024-04-05 | — | — | CN | disclosed |
| US-20240101553-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2024-03-28 | — | — | US | disclosed |
| US-20230373999-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230121086-A1 | RORgT INHIBITOR, PREPARATION METHOD THEREOF AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2023-04-20 | — | — | US | disclosed |
| EP-3710439-B1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-02-15 | — | — | EP | disclosed |
| EP-4089080-A1 | RORyT INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | Sunshine Lake Pharma Co., Ltd. (CN) | 2022-11-16 | — | — | EP | disclosed |
| WO-2021139595-A1 | RORγT INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 东莞市东阳光新药研发有限公司 | 2021-07-15 | — | — | WO | disclosed |
| US-20200262837-A1 | KRAS G12C INHIBITORS | ARRAY BIOPHARMA INC. | 2020-08-20 | — | — | US | disclosed |
| US-10689377-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2020-06-23 | — | — | US | disclosed |
| US-10633381-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2020-04-28 | — | — | US | disclosed |
| WO-2009010804-A1 | MACROCYCLIC COMPOUNDS AS ANTIVIRAL AGENTS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2009-01-22 | — | — | WO | disclosed |
| US-7304081-B2 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2007-12-04 | — | — | US | disclosed |
| US-7279584-B2 | Method for production of cis-4-fluoro-L-proline derivatives | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2007-10-09 | — | — | US | disclosed |
| US-20070043010-A1 | Quinazoline derivatives | ASTRAZENECA UK LIMITED (GB) | 2007-02-22 | — | — | US | disclosed |
| US-20060281927-A1 | Process for production of cis-4-fluoro-l-proline derivatives | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2006-12-14 | — | — | US | disclosed |
| US-20060276449-A1 | 1,3-Dihydro-2h-indol-2-one derivative | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2006-12-07 | — | — | US | disclosed |
| US-20050282858-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2005-12-22 | — | — | US | disclosed |
| US-6855708-B2 | N-arylsulfonyl aza-bicyclic derivatives as potent cell adhesion inhibitors | MERCK & CO., INC. (US) | 2005-02-15 | — | — | US | disclosed |
| US-6552016-B1 | For inhibiting aberrant growth states resulting from hedgehog gain- of-function, ptc loss-of-function or smoothened gain-of-function comprising contacting the cell with a hedgehog antagonist, such as a small molecule | CURIS, INC. | 2003-04-22 | — | — | US | disclosed |
| US-20030008861-A1 | N-arylsulfonyl aza-bicyclic derivatives as potent cell adhesion inhibitors | MERCK & CO., INC. | 2003-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10633381-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | CHRM2 4880/4885CHRM1 4874/4885CHRM3 4879/4885 |
| US-20200262837-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | CHRM2 4880/4885CHRM1 4874/4885CHRM3 4879/4885 |
| US-20070043010-A1 | Quinazoline derivatives | ERBB2, ABL1, EGFR | CHRM2 3284/4885CHRM1 2748/4885CHRM3 3405/4885 |
| US-20060276449-A1 | 1,3-Dihydro-2h-indol-2-one derivative | AVPR1B, AVPR2, AVPR1A | CHRM2 181/4885CHRM1 112/4885CHRM3 255/4885 |
| US-10689377-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | CHRM2 4880/4885CHRM1 4874/4885CHRM3 4879/4885 |
| US-20050282858-A1 | Amido compounds and their use as pharmaceuticals | HSD11B1, CYP11B1, HSD11B2 | CHRM2 3175/4885CHRM1 2365/4885CHRM3 2500/4885 |
| US-20240101553-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | CHRM2 4880/4885CHRM1 4874/4885CHRM3 4879/4885 |
| US-20060281927-A1 | Process for production of cis-4-fluoro-l-proline derivatives | PRAP1, P4HA1, SLC6A7 | CHRM2 3769/4885CHRM1 2830/4885CHRM3 4285/4885 |
| US-20030008861-A1 | N-arylsulfonyl aza-bicyclic derivatives as potent cell adhesion inhibitors | VCAM1, CD4, ITGA4 | CHRM2 897/4885CHRM1 586/4885CHRM3 1189/4885 |
| US-20230121086-A1 | RORgT INHIBITOR, PREPARATION METHOD THEREOF AND USE THEREOF | RORC, RORB, RORA | CHRM2 4683/4885CHRM1 4646/4885CHRM3 3863/4885 |
| US-20230373999-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | CHRM2 4880/4885CHRM1 4874/4885CHRM3 4879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.